Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165154 | 1.00 | MKNK1 (0.55) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL7992297 | 1.00 | MKNK1 (0.55) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL3717223 | 0.94 | MEN1 (0.51) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL8541954 | 0.92 | MEN1 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL7672102 | 0.92 | MEN1 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL11510901 | 0.89 | MKNK1 (0.48) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL25625502 | 0.85 | MAPT (0.48) | MKNK1CHRNB2CHRNA4CYP2D6MEN1 | |
| SCHEMBL24775559 | 0.81 | CHRNB2 (0.52) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL21507863 | 0.80 | MEN1 (0.42) | MKNK1CHRNB2CHRNA4CYP2D6MEN1 | |
| SCHEMBL6557404 | 0.79 | CHRNB2 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978311-B | Cell apoptosis inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-05-31 | — | — | CN | disclosed |
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | Micro Labs Ltd. (IN) | 2022-05-31 | — | — | US | disclosed |
| US-20210094918-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS | Micro Labs Ltd. (IN) | 2021-04-01 | — | — | US | disclosed |
| WO-2021001713-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL, ITS SALTS & POLYMORPHS | MICRO LABS LIMITED (IN) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | MKNK1 4532/4885CHRM2 284/4885CHRM5 184/4885 |
| US-20210094918-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS | VKORC1L1, CYP3A4, REN | MKNK1 2491/4885CHRM2 1589/4885CHRM5 1719/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | MKNK1 1073/4885CHRM2 3571/4885CHRM5 3306/4885 |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | MKNK1 4020/4885CHRM2 4780/4885CHRM5 4534/4885 |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | VKORC1L1, CYP3A4, REN | MKNK1 2491/4885CHRM2 1589/4885CHRM5 1719/4885 |
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, TNF, BAD | MKNK1 3471/4885CHRM2 4879/4885CHRM5 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.